ChromaDex trims loss, reports $65 million in orders for Niagen ingredient
From a reported loss in the fiscal year 2013, ChromaDex Corp. announces its continuing investment on Niagen ingredient with $65 million worth in orders for Niagen ingredient. The inbound inquiries the company is receiving regarding Niagen continue to be beyond previous expectation. In 2013, the company licensed from Washington University exclusive worldwide patent rights related to the recently discovered vitamin, nicotinamide riboside (“NR”) covering its use for prevention or treatment of neuropathies caused by axon degeneration. ChromaDex announced a 3-year marketing deal with Thorne Research, Inc. and 4-year ingredient supply with direct marketing company 5LINX. The company launched NIAGEN, the branded form of the ingredient, in May.